Chapter 77: Drug Therapy for Rheumatoid Arthritis

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Um,

imagine your own immune system just, you know, suddenly deciding your joints are an invading army.

Yeah, it really sounds like science fiction.

Right.

But I mean, that is the daily reality for over 1 .3 million Americans living with rheumatoid arthritis.

And fighting back requires this, well, it's a lifelong high speaks game of pharmacological chess.

It absolutely is.

So you are stepping into a very special last minute lecture edition of our deep dive.

If you're listening to this right now, you're likely a nursing student staring down a massive pharmacology exam on rheumatoid arthritis drugs.

And that can be incredibly intimidating.

I mean, the sheer volume of medications.

Oh yeah.

The side effects, the black box warnings, it's a lot.

It feels completely overwhelming at first glance.

Exactly.

So our mission today is to translate all of that dense LAN A chapter 77 information into a really clear, memorable mental map.

We want the clinical reasoning behind every single medication decision to just, you know, click into place for you.

Right.

And to understand how these really powerful immunosuppressants and targeted therapies actually work, we first have to understand the battlefield they're deployed on.

The actual joints.

Yeah.

Before we can stop the destruction, we need to zoom in on the microscopic level to see what the immune system is actively doing.

So rheumatoid arthritis, or RA, is primarily an autoimmune inflammatory disorder.

And it usually targets a younger demographic than typical wear and tear arthritis.

Exactly.

It often hits people in their thirties and forties.

And interestingly, women are actually three times more likely to develop it than men.

Wow.

Three times more likely.

And the hallmark signs are super distinct.

Like a patient will present with symmetric joints, stiffness, and pain.

Symmetric being the key word there.

Right.

Meaning if the right wrist is inflamed, the left wrist usually is too.

And the pain typically feels worst in the morning and gets slightly better as the day progresses, you know.

Yeah.

The joints themselves become noticeably swollen, tender,

and really warm to the touch.

But the critical piece for a nurse to remember for the exam is that RA isn't just a localized joint problem.

It's systemic.

Exactly.

It's a systemic disease.

Because the whole immune system is in overdrive,

patients experience fevers, extreme fatigue, weight loss, thinning of the skin, and even severe vasculitis.

Which is that really dangerous inflammation of the blood vessels.

Right.

And if you visualize the physical progression of the joint damage, the pathology starts to make complete sense.

So a healthy joint consists of two bones lined with smooth articular cartilage.

To keep things gliding.

Yeah.

And the whole mechanism is encased in a protective synovial membrane.

That membrane secretes fluid to keep everything lubricated.

But in RA, the immune system mistakenly targets that exact synovial membrane.

So it attacks the area, the membrane becomes inflamed, it thickens, and it aggressively grows over the cartilage.

This destructive kind of weed -like overgrowth of tissue is called the panus.

The panus.

Okay.

And that panus tissue isn't just like taking up space, right?

It's actively waging war.

Oh, absolutely.

It releases these powerful enzymes that literally eat away at the articular cartilage.

Just dissolving it.

Right.

And while that's happening, the overall inflammatory process is churning out chemical cytokines into the synovial space.

The main villains driving this destruction are tumor necrosis factor, or TNF, and then interleakins 1 and 6.

TNF IL -1 and IL -6.

Got it.

So as those cytokines command the attack, the cartilage is totally destroyed.

And eventually the exposed bones end up rubbing directly against each other and permanently fused together.

Which halts all movement completely.

Which is terrifying.

So if the immune system is essentially remodeling the joint with this destructive panus tissue,

like how fast do we have to act?

Incredibly fast.

I mean, the medical response has to be very aggressive.

Current clinical guidelines mandate that a patient must be started on a disease -modifying antirheumatic drug, a D -Omard, within three months of an RA diagnosis.

Three months.

That's a tight window.

It is.

Because the goals of therapy aren't just about making the patient comfortable anymore.

We have to maintain joint function, minimize that systemic vascular involvement, and physically delay the disease progression.

But there's a massive pharmacological catch here that dictates the whole treatment strategy, right?

D -Mards are slow.

Extremely slow.

But they took weeks, sometimes several months, to alter the immune system enough to actually start working.

So if a patient is sitting in a clinic in absolute agony today, their joints are actively inflamed, we can't just hand them a D -Mart and say, hang in there for two months.

No, absolutely not.

Which brings us to a vital clinical concept.

The bridge.

The bridge.

Right.

Because those disease -modifying drugs are so slow to activate, we have to use fast -acting anti -inflammatory drugs as a bridge.

They relieve the symptoms immediately and hold the line while the heavy hitters ramp up in the background.

Okay, so the two main pillars of this bridge are NSAIDs and glucocorticoids.

Let's focus on NSAIDs first.

Sounds good.

Non -steroidal anti -inflammatory drugs provide rapid symptom relief by inhibiting the cyclooxygenase enzyme, known as COX.

But the absolute most important takeaway here for the exam is that NSAIDs do not slow down the actual disease progression.

Right.

They are purely masping the symptoms.

Exactly.

Just reducing the immediate swelling.

The underlying joint destruction from the panacea is still happening.

Yeah.

And the mechanism of that COX inhibition explains the intense side effect profile you have to monitor.

NSAIDs are divided into first -generation and second -generation.

Okay.

First -generation NSAIDs inhibit both COX -1 and COX -2 enzymes.

COX -2 is the enzyme responsible for producing the prostaglandins that cause inflammation and pain at the joint.

We definitely want to block that.

We do.

But COX -1 is the enzyme that produces the specific prostaglandins responsible for maintaining the protective mucosal lining of the stomach.

Oh, I see.

So when a first -generation NSAID blocks COX -1, it literally strips away the stomach's defenses against its own acid.

Exactly.

Leading to a super high risk for profound gastrointestinal ulceration and severe bleeding.

Which brings us to the second -generation NSAIDs, right?

The coxibs.

They were designed to selectively inhibit only COX -2.

Right.

They spare the COX -1 enzyme, which sounds like the perfect solution to protect the stomach.

But altering the body's chemistry always has a trade -off.

Always.

While selective COX -2 inhibitors reduce that GI bleeding risk, they inadvertently suppress the production of prostacyclin.

Prostacyclin.

Yeah.

It's a chemical that normally prevents blood vessels from constricting and stops platelets from clumping.

So without prostacyclin keeping things flowing smoothly, the patients risk for thrombotic events.

Like heart attacks and strokes.

Exactly.

That risk spikes significantly.

Wow.

And the dosages required for RA make these risks incredibly dangerous.

I mean, if you have a normal tension headache, you might take a couple of aspirin tablets.

Yeah.

But to achieve the profound anti -inflammatory effects needed to quiet an RA flare -up, a patient might be prescribed up to 5 .2 grams of aspirin a day.

It's a massive dose.

That's the equivalent of 16 standard tablets.

At those massive doses, the GI and bleeding risks are just an ever -present threat.

They really are.

And the other option for the bridge is glucocorticoids.

These are immensely powerful steroidal anti -inflammatories.

And unlike NSAIDs, glucocorticoids actually can slow the disease progression in the short term, right?

They can.

They aggressively suppress the inflammatory pathways and immune cell function.

But the long -term toxicity of glucocorticoids is severe.

Right.

We're talking about accelerated osteoporosis because steroids interfere with bone formation.

They cause severe gastric ulceration.

And critically, they cause adrenal suppression.

Yes.

That's a huge one for nursing students to know.

If you supply the body with high doses of exogenous steroids, the body's own adrenal glands just, well, they go to sleep.

They stop making natural cortisol.

You can never just abruptly stop a glucocorticoid.

Otherwise, the patient goes into an adrenal crisis because their body has forgotten how to make its own stress hormones.

Exactly.

And because of these systemic toxicities, glucocorticoids are typically limited to short courses just to control severe temporary flare -ups.

So let me ask you this.

The overlapping risks here create a massive nursing implication.

If both NSAIDs and glucocorticoids cause stomach ulcers,

what happens if patient takes both at the same time?

It's a great question.

If they're on both, the risk for major gastrointestinal bleeding and adverse ulceration increases fourfold.

Fourfold.

Wow.

Yeah.

So as a nurse, you should expect the provider to discontinue the NSAID whenever the patient is placed on a course of glucocorticoids.

Managing that overlap is absolutely crucial for safety.

Okay.

So the bridge medications are like the fire extinguishers putting out the visible flames, but they aren't fixing the faulty wiring that's causing the immune system fire in the first place.

Great analogy.

Once the immediate pain is managed, the clinical focus shifts to shutting off that faulty wiring.

Which brings us to our first line of defense to fundamentally alter the disease.

Conventional DMARDS.

Right.

Conventional or traditional DMARDS are small chemically synthesized molecules.

They work by broadly suppressing the entire immune system to halt the attack on the joints.

But because they indiscriminately turn down the body's immune response, the core risks spanning this entire drug class are infection, hepatotoxicity, and bone marrow suppression.

Exactly.

And the absolute standard bearer here, the prototype for the class, is methotrexate.

It's widely considered the drug of first choice by rheumatologists because it acts relatively fast for a DMARD.

Fast meaning what?

Three to six weeks.

Yeah.

Typically showing therapeutic effects in about three to six weeks.

Methotrexate is fundamentally a folate antagonist.

Okay.

And to understand its toxicity, you have to understand how folate antagonism works.

Cells need folic acid to synthesize DNA and divide, right?

Right.

By blocking folate, methotrexate essentially starves rapidly dividing cells.

Since the rogue immune cells attacking the joints are dividing rapidly, they get halted.

But the body has other healthy cells that also rely on rapid division.

Exactly.

Specifically, the cells in the bone marrow, the mucosal lining of the gastrointestinal tract, and hair follicles.

And that mechanism explains the severe safety alerts.

Methotrexate can cause fatal toxicities of the bone marrow, leading to dangerously low white blood cell, red blood cell, and platelet counts.

It's really serious.

It can cause severe liver damage and pulmonary toxicity.

So as a nurse on the floor,

the monitoring is rigorous.

You need a baseline and periodic complete blood count to watch for that bone marrow suppression.

You also have to monitor liver and renal function tests.

And crucially, because the immune system is being suppressed, you must screen the patient for latent tuberculosis before starting therapy.

Because this suppressed immune system could allow dormant TB to just reactivate and take over.

Exactly.

And to help mitigate the collateral damage to the liver and the GI tract, patients are almost always prescribed a concurrent folic acid supplement, usually at least five milligrams a week.

Which provides just enough folate to protect the healthy cells without overriding the drug's effect on the disease.

Right.

Additionally, because the immune response is so blunted, live vaccines are completely contraindicated.

The patient's body just wouldn't be able to mount a defense against the weakened virus in the vaccine.

So all required immunizations have to be completed before methotrexate therapy begins.

Another critical clinical mechanism relates to pregnancy.

Because methotrexate halts cellular division and DNA synthesis,

it is highly teratogenic.

It causes fetal death and severe congenital abnormalities.

So it's absolutely contraindicated during pregnancy.

And this profound teratogenic risk also applies to the next conventional DMARD on the list, leflunamide.

Leflunamide.

Yeah, it is generally considered just as effective as methotrexate, but it's actually much more hazardous.

Because of the clearance mechanism, right?

The clearance process for leflunamide is just fascinating, especially for patients of childbearing age.

If a patient on leflunamide decides they want to get pregnant, or if a male patient wants to father a child, they can't just stop taking the pill and wait a few weeks.

No, the drug undergoes this process called n -erohepatic recirculation.

Right.

The liver excretes the drug in bile into the intestines, but instead of being eliminated, the intestines just reabsorb it back into the bloodstream in this continuous loop.

So without intervention, leflunamide can remain in the body at highly teratogenic levels for two solid years after the last dose.

That's wild.

It's like having to do a chemical deep cleanse of your entire body just to safely have a baby.

It really is.

To break that cycle, the patient has to undergo a strict 11 -day washout protocol.

They are prescribed a medication called cholesteramine.

Cholesteramine acts like a chemical magnet in the intestines.

It binds directly to the leflunamide in the gut, preventing it from being reabsorbed back into the bloodstream and forces it to be excreted in the stool.

This effectively flushes the medication out of the system safely.

Wow.

Moving on, the next conventional demard is sulfasalazine, which can slow joint deterioration quite quickly, sometimes showing results in just a month.

But it carries unique risks based on its chemical structure, right?

Yeah.

When ingested, it splits in the gut into an anti -inflammatory component and a sulfa component.

And because of that sulfa component, the drug is strictly contraindicated for any patient with a known sulfa allergy.

And what are the major complications there?

The major complications are gastrointestinal issues and severe dermatologic reactions.

Specifically, it can trigger Stevens -Johnson syndrome.

Which is that rare, severe immune hypersensitivity reaction where the top layer of skin, the epidermis, actually separates from the underlying dermis.

Right.

It presents as a spreading rash and blisters, and it can be fatal.

Any sign of an unexplained rash on sulfasalazine requires immediate intervention.

Good to know.

And the last major conventional demard is hydroxychloroquine, an anti -malarial drug that is usually combined with metotrexate to boost its efficacy.

The defining toxicity for hydroxychloroquine is irreversible retinal damage.

Blindness.

Yeah.

The drug has a high chemical affinity for melanin, the dark pigment in the body.

The macula and the retina of the eye are incredibly rich in melanin, so the drug actually accumulates in the eye over time, slowly poisoning the retinal cells.

So patients must undergo a thorough baseline ophthalmology exam and receive annual eye exams while on the medication.

Exactly.

It also poses a cardiovascular risk by prolonging the QT interval, which can lead to dangerous heart arrhythmias.

Okay, so if we group these conventional D .R .s by organ system, it creates a perfect mental checklist for nursing assessments.

Let's recap.

Methotrexate targets the liver, bone, marrow, and lungs.

Laflutamide requires that intense cholesterol mean washout due to severe pregnancy risks.

Sulfasalazine attacks the skin through Stevens -Johnson syndrome, and hydroxychloroquine accumulates in the eyes and affects the heart rhythm.

Spot on.

So conventional D .R .s suppress the immune system broadly, kind of like throwing a heavy blanket over a fire.

But science has developed larger, smarter weapons designed to target the exact immune signals causing the joint damage.

Enter the biologic D .R .s.

Yes.

Biologic D .R .s are massive, complex molecules produced using recombinant DNA technology.

Because they're biologically engineered, they are incredibly expensive, often costing tens of thousands of dollars a year.

And the most prominent group of biologics used in R .A.

are the tumor necrosis factor, or TNF, inhibitors.

These include drugs like adalimumab, sertalizumab, infliximab, and our primary prototype, etanercept.

Right.

We established earlier that TNF is a major cytokine mediating the destruction of the joint.

TNF floating in the synovial fluid stimulates the production of factors that pull destructive neutrophils and macrophages directly into the joint space.

So etanercept is an engineered molecule designed to mimic the body's natural TNF receptors.

Functions like a chemical sponge, right?

A targeted sponge, yes.

Yeah.

After it's administered, it circulates and binds up all the free -floating TNF in the body before that TNF can ever reach the actual receptors on the patient's joint tissues.

It's essentially a decoy on the battlefield, soaking up the chemical signals or arrows before they can trigger the inflammatory cascade and hit the castle walls.

Great way to picture it.

And etanercept is administered subcutaneously because it's a large protein being injected under the skin.

Localized injection site reactions are incredibly common.

Like redness, swelling, and itching that resolves in three to five days.

But the systemic consequences of soaking up the body's TNF supply result in some really severe black box warnings.

They do because TNF isn't just an antagonist on RA, it's a vital component of the human immune system, specifically necessary for fighting off intracellular infections.

Like tuberculosis.

Exactly.

If a person is exposed to tuberculosis, their immune system might not kill the bacteria, but it will build a wall of cells, a granuloma around the TB, to trap it in a dormant state.

TNF is the chemical mortar holding that cellular wall together.

Oh wow.

So an etanercept blocks the TNF that mortar dissolves.

The wall crumbles and the dormant tuberculosis bacteria escape, causing an active life -threatening infection.

That's the exact mechanism.

Blocking TNF leaves the door wide open for bacterial sepsis, invasive fungal infections, and opportunistic pathogens.

So the absolute priority nursing intervention is that you must rigorously test the patient for latent tuberculosis and hepatitis B before ever administering a biologic.

Absolutely.

If they test positive, you have to fully treat the TB or the hep B infection before initiating etanercept.

Furthermore, the black box warning highlights an increased risk for lymphoma and other malignancies, particularly in kids and teens.

It can also worsen existing heart failure or cause new onset cases, and it's associated with rare central nervous system demyelinating disorders that mimic multiple sclerosis.

There's a lot to monitor.

Yeah.

Now another major TNF inhibitor is infliximab.

And while it shares the same profound infection risks, it differs significantly in its administration.

Infliximab is given as an intravenous infusion.

Right.

And because infliximab is a chimeric monoclonal antibody.

Meaning its molecular structure is made from a combination of human and mouse proteins.

Exactly.

The human body often recognizes those mouse proteins as foreign invaders.

Up to 18 % of patients develop severe infusion reactions.

Ranging from flu -like symptoms and hypotension to full -blown anaphylaxis.

So the nursing protocol requires pre -medicating the patient with antihistamines, acetaminophen, and sometimes glucocorticoids before starting the IV just to blunt this immune reaction.

Okay.

Real quick on the other biologics.

They target different cellular mechanisms entirely.

Rituximab works by intentionally depleting the body's B cells.

And that profound suppression carries a terrifying black box warning for progressive multifocal leukoencephalopathy or PML, which is a severe, often fatal, viral infection of the brain.

Right.

Then abatacept inhibits T cell activation.

And tocilizumab is an interleukin -6 receptor antagonist.

A unique high -yield clinical fact for tocilizumab is a high risk of gastrointestinal perforation, making it particularly dangerous for patients who have a pre -existing history of diverticulatus.

Excellent summary.

So biologics operate outside the cells, intercepting cytokines in the bloodstream.

But the newest evolution in RA therapy goes a step further.

They sneak inside.

Yes.

These medications sneak inside the immune cells to shut down the cellular machinery itself.

These are the targeted deons, specifically the Janus kinase or JS inhibitors.

The prototype drug is tefocetinibib.

Tefocetinib.

Okay.

And unlike the massive biologic proteins, tefocetinib is a synthetic small molecule, which means it can be administered orally, right?

Yes, given orally.

And the mechanism of action is fascinating.

Cytokines outside the cell bind to receptors, but they need a way to transmit their inflammatory message all the way down to the cell's nucleus to actually change the cell's behavior.

So JK enzymes are the internal messengers that carry that signal through what is called the stat signaling pathway.

Exactly.

Tefocetinib inhibits the JAK enzymes, essentially cutting the internal communication wires.

The cell receives the inflammatory signal on the outside, but the message never reaches the nucleus.

So the immune response is halted from the inside out.

Right.

Tefocetinib is typically reserved for patients who have failed methotrexate therapy.

But shutting down profound cellular signaling pathways comes with a steep clinical price, doesn't it?

The FDA issued a major safety alert for JAK inhibitors based on a large post -marketing study.

They did.

The study revealed an association with increased overall mortality.

Patients taking tefocetinib developed higher rates of lymphoma and other cancers, but the most striking finding was a significant increase in thrombosis, severe blood clots, leading to myocardial infarctions and strokes.

Wow.

So the clinical takeaway for the nurse is that monitoring a patient on a JAK inhibitor goes far beyond just watching for signs of infection.

You are acutely monitoring for signs of cardiovascular events, deep vein thrombosis and pulmonary embolisms.

Yes.

Additionally, because the immunosuppression from cutting the JAK stat pathway is so profound, you can never combine a JAK inhibitor with a biologic DMARD.

Because the additive suppression would render the patient completely defenseless against fatal infections.

All right.

When we synthesize everything we've explored, the primary nursing lens for a patient with rheumatoid arthritis becomes incredibly clear.

First, it requires recognizing high -risk patients.

So screening for latent infections like TB or Hep B, noting a history of liver disease and assessing for heart failure risks.

Second, it demands diligent, continuous monitoring of laboratory values.

You are constantly pulling complete blood counts to check for plummeting white cells and platelets, tracking comprehensive metabolic panels and verifying liver function tests.

And third, you're educating the patient.

They must understand they are immunocompromised.

They need to be taught to avoid crowds and to immediately report persistent fevers, unexplained bruising or signs of liver injury like right -sided abdominal pain or yellowing of the skin.

If I can leave you with a clinical reasoning challenge as you prepare for this exam, it is this.

The next time you see a patient with rheumatoid arthritis on a medication list, don't just look at the specific drug name, look at the timeline.

Timeline, right.

Are they on an NSAI or a glucocorticoid bridge because they were just diagnosed and are in acute pain?

Are they on methotrexate, waiting out that three to six -week period for the broad suppression to kick in?

Or have they escalated to a biologic like etanerset or a targeted JAKE inhibitor like tefasetetinib because the joint damage is aggressively advancing and conventional therapy failed?

The drug they are taking tells you the exact story of their disease progression.

You aren't just memorizing an alphabet soup of side effects.

You are reading the patient's history through their chart.

You are stepping into that high state's lifelong chess match against their immune system.

And now you know exactly how all the pieces on the board move.

You really do.

You've got this exam in the bag.

On behalf of the Last Minute Lecture team, thank you for diving into the pharmacology with us.

Take a deep breath, trust your knowledge, and go ace that test.